Bayer's Two-Front Advance: Japan Approval and Pipeline Data Vie With a Rescheduled Roundup Hearing

Bayer's pharma gains momentum with Japan's Sevabertinib approval and China filing, while Roundup settlement hearing delayed to September 14.

Bayer's pharma division is putting distance between itself and the legal baggage of the past, with regulatory wins stacking up across Asia even as the company's most persistent overhang — the glyphosate litigation — refuses to fade from view. The latest milestone came Tuesday when Japanese authorities cleared Sevabertinib, to be marketed as Hyrnuo, for patients with HER2-mutated, unresectable non-small cell lung carcinoma, a cancer subtype that has historically resisted effective treatment.

The approval lands as the Leverkusen-based group prepares to showcase its broader R&D ambitions. Bayer has confirmed it will present fresh Phase III data from its cardiovascular, renal and stroke programs at the ESC Congress 2026 in Munich, running from Friday to Monday. That dual thrust — a commercial oncology win in Japan and a pipeline data drop in Europe — underscores a deliberate strategy to diversify the pharma portfolio rather than hinge its fortunes on any single compound.

Regulatory Momentum Across Asia

Japan is not the only market where Bayer is pressing its advantage. In China, the National Medical Products Administration has accepted the company's filing for Aflibercept 8 mg, intended to treat macular edema following retinal vein occlusion. The parallel regulatory tracks in two of Asia's largest healthcare markets signal that the pharma segment is gaining substance even as the crop science division continues to drag on group performance.

These developments align with the picture Bayer painted in its second-quarter results earlier this month. The company reported currency-adjusted sales growth of 2.2 percent to EUR 10.9 billion, with EBITDA before special items coming in at EUR 2.1 billion. Management reaffirmed its full-year guidance despite the agricultural headwinds, leaning heavily on debt reduction and operational execution as the pillars of its investor narrative.

The Legal Calendar Takes Center Stage

Yet for all the progress in the lab and the clinic, the Roundup settlement remains the defining risk for shareholders. The court hearing originally scheduled for August 19 to grant final approval to the $7.25 billion settlement has been pushed back to September 14 — the second postponement the process has endured. Each delay prolongs the uncertainty around a legal overhang that has weighed on the stock for years, even if it has done little to derail the recent rally.

The market's response to the pharma news has been measured rather than exuberant. The shares closed Wednesday at EUR 48.92, down 0.6 percent on the day, though that modest pullback does little to dent a broader recovery that has seen the stock gain 32 percent year-to-date and 72 percent over the past twelve months. At current levels, the shares sit roughly 9.2 percent below their 52-week high of EUR 53.86 and trade about 19 percent above their 200-day moving average of EUR 41.11 — technical markers that suggest the medium-term uptrend remains firmly intact.

A Fortnight That Could Define the Next Chapter

The coming weeks present a compressed window of catalysts. The ESC Congress will deliver a read on Bayer's cardiovascular ambitions, while the September 14 hearing will test the durability of the settlement framework. With 30-day realized volatility at 23 percent, the shares are primed for short-term swings as investors weigh clinical headlines against legal risk.

For now, the narrative is one of a company executing on two fronts simultaneously: advancing a pharma pipeline that is beginning to deliver tangible regulatory outcomes, while managing a legal legacy that will not be resolved until the courts have their say. The next fortnight promises to sharpen that picture considerably.